We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MEI Pharma-Presage Biosciences on License Deal for Voruciclib
Read MoreHide Full Article
MEI Pharma, Inc. (MEIP - Free Report) announced that it has inked an exclusive license agreement with Presage Biosciences, an oncology company, for developing its oral and selective cyclin-dependent kinase (CDK) inhibitor, voruciclib (formerly P1446A), for treatment of B-cell lymphoma 2 (BCL2).
Pursuant to the agreement, MEI Pharma wins exclusive rights to develop, manufacture and commercialize voruciclib globally. On the other hand, Presage will be entitled to receive near-term payments of $2.9 million along with $181 million upon achieving certain development, plus regulatory and commercial milestones. Also, on successful development of any product, Presage will be entitled to receive mid single-digit tiered royalties on the net sales.
MEI Pharma’s shares have increased more than 5% following the news. Also, shares of the company have significantly outperformed the industry so far this year. The stock has surged 95.8% versus the industry’s 2.2% increase during the period.
MEI Pharma also informed that the agreement provides an efficient development path in combination with Roche’s (RHHBY - Free Report) BCL2 inhibitor, Venclexta (venetoclax). The company also believes that the deal will enable both the parties to utilize MEI Pharma’s CIVO intratumoral microdosing platform for advancing additional candidates and combinations to treat various types of cancers.
We remind investors that voruciclib boasts an established clinical safety profile. The candidate has been evaluated in many phase I studies with more than 70 patients. Additionally, in pre-clinical studies, voruciclib alone demonstrated cell death in multiple patients with chronic lymphocytic leukemia (CLL).
Notably, presently Pfizer’s (PFE - Free Report) Ibrance (palbociclib) and Novartis’ (NVS - Free Report) Kisqali (ribociclib) are two CDK inhibitors approved in the United States for treating HER2 negative breast cancer combined with hormonal therapy. Hence, voruciclib is expected to confront competition on approval, given presence of established products in the targeted space.
However, the agreement will expand MEI Pharma’s oncology portfolio and offer additional opportunities to improve the lives of patients suffering from cancer.
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
Image: Bigstock
MEI Pharma-Presage Biosciences on License Deal for Voruciclib
MEI Pharma, Inc. (MEIP - Free Report) announced that it has inked an exclusive license agreement with Presage Biosciences, an oncology company, for developing its oral and selective cyclin-dependent kinase (CDK) inhibitor, voruciclib (formerly P1446A), for treatment of B-cell lymphoma 2 (BCL2).
Pursuant to the agreement, MEI Pharma wins exclusive rights to develop, manufacture and commercialize voruciclib globally. On the other hand, Presage will be entitled to receive near-term payments of $2.9 million along with $181 million upon achieving certain development, plus regulatory and commercial milestones. Also, on successful development of any product, Presage will be entitled to receive mid single-digit tiered royalties on the net sales.
MEI Pharma’s shares have increased more than 5% following the news. Also, shares of the company have significantly outperformed the industry so far this year. The stock has surged 95.8% versus the industry’s 2.2% increase during the period.
MEI Pharma also informed that the agreement provides an efficient development path in combination with Roche’s (RHHBY - Free Report) BCL2 inhibitor, Venclexta (venetoclax). The company also believes that the deal will enable both the parties to utilize MEI Pharma’s CIVO intratumoral microdosing platform for advancing additional candidates and combinations to treat various types of cancers.
We remind investors that voruciclib boasts an established clinical safety profile. The candidate has been evaluated in many phase I studies with more than 70 patients. Additionally, in pre-clinical studies, voruciclib alone demonstrated cell death in multiple patients with chronic lymphocytic leukemia (CLL).
Notably, presently Pfizer’s (PFE - Free Report) Ibrance (palbociclib) and Novartis’ (NVS - Free Report) Kisqali (ribociclib) are two CDK inhibitors approved in the United States for treating HER2 negative breast cancer combined with hormonal therapy. Hence, voruciclib is expected to confront competition on approval, given presence of established products in the targeted space.
However, the agreement will expand MEI Pharma’s oncology portfolio and offer additional opportunities to improve the lives of patients suffering from cancer.
MEI Pharma, Inc. Price
MEI Pharma, Inc. Price | MEI Pharma, Inc. Quote
Zacks Rank
MEI Pharma currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>